Evolocumab
Myocardial Infarction
Amgenmonoclonal_antibodyPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Myocardial Infarction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | A |
Plavix Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | A |
Ticagrelor Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
Vitamin B6 Hamilton Health Sciences Corporation | Phase 4 | BBB |
Folic Acid Hamilton Health Sciences Corporation | Phase 4 | BBB |
View all 37 →
Same molecule, other indications
Evolocumab is also rated in:
Subjects With Hyperlipidemia, Dyslipidemia and HIV InfectionDormant
B
Indicative ·
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →